| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 58.94 | 16.2% | 1.9% |
| Total Income | 63.35 | 13.1% | 3.1% |
| Expenditure | 59.04 | 16.0% | 22.4% |
| PBT | 7.79 | 64.6% | 65.5% |
| Net Profit | 4.75 | 70.8% | 70.8% |
| OPM | 8.42% | 19.72pp | 25.89pp |
| NPM | 7.49% | 14.80pp | 18.99pp |
| EPS | 1.47 | 71.0% | 71.0% |
Core chemicals revenue grew only 1.9% YoY while adjusted net profit fell 70.8% on margin collapse (OPM 34.3%→8.4%), a clear sector deterioration.
Indo Borax H1FY27 Income Up 16% to ₹129.29 Cr; Acquires Kronox Lab
11 Nov 2026 · 11 Nov, 2:03 pm
Summary
Indo Borax & Chemicals Ltd reported a 16.0% growth in consolidated operating income for H1FY27, reaching Rs. 129.29 crore. Adjusted EBITDA also saw a substantial increase of 22.9% to Rs. 28.09 crore, with an Adjusted EBITDA margin of 21.7%. Profit After Tax, however, declined to Rs. 21.00 crore in H1FY27 from Rs. 26.47 crore in the prior year period. Management cited steady demand but pressure on profitability due to higher raw material costs and geopolitical uncertainties, while expressing confidence in sustaining growth momentum through diversification and disciplined execution.
Key Highlights
- 1
Consolidated operating income for H1FY27 grew by 16.0% to Rs. 129.29 crore, up from Rs. 111.42 crore in H1FY26.
- 2
Adjusted EBITDA for H1FY27 stood at Rs. 28.09 crore, marking a significant increase of 22.9% compared to the previous period.
- 3
The company's consolidated Profit After Tax for H1FY27 was Rs. 21.00 crore, a decrease from Rs. 26.47 crore in H1FY26.
- 4
For Q2FY27, consolidated operating income was Rs 58.94 crore, a slight increase from Rs 57.85 crore in Q2FY26.
- 5
The company completed its acquisition of a 64.26% stake in Kronox Lab Sciences Ltd, appointing Mr. Suresh Kalra as its Managing Director and Chief Executive Officer.
- 6
Board approval was received for the amalgamation of its wholly owned subsidiary, Indoborax Infrastructure Private Ltd, with Indo Borax Chemicals, subject to regulatory approvals.
Management Comments
Suresh Kalra
The quarter under review witnessed steady demand across our key product segments, despite the seasonal impact of the monsoon. However, profitability remained under pressure due to higher raw material costs and geopolitical uncertainties in the Middle East, thereby impacting the overall cost environment. We will continue to focus on operational efficiencies, prudent cost management and optimising product mix to navigate these challenges in the coming quarters.
Suresh Kalra
The quarter under review also witnessed strategic integration and stabilisation of synergies with the recently acquired Kronox Lab Sciences, in terms of markets of distribution and procurement ecosystem. Going forward, we are confident of sustaining the growth momentum and strengthening our margins further, backed by diversification, premiumisation and disciplined execution.
Suresh Kalra
We expect the proposed amalgamation to unlock greater operational efficiencies by enabling the pooling and optimal utilisation of resources across the combined entity. It will also facilitate sharper management focus, simplify governance structures and enable more agile decision-making, thereby creating a more integrated and efficient organisation.
Informational and educational content only. Not investment advice.